5 Best Undervalued Stocks to Invest In Right Now

3. AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) is one of the best undervalued stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on March 2 positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab subcutaneous induction treatment versus placebo in adult patients with moderately to severely active Crohn’s disease. The company reported that results from the study show notably higher proportions of patients treated with risankizumab SC induction attained the co-primary endpoints of Crohn’s Disease Activity Index clinical remission and endoscopic response at week 12 compared to placebo.

Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie Inc. (NYSE:ABBV), stated that the level of endoscopic response marks a particularly meaningful achievement for Crohn’s disease patients, and that these results highlight the company’s continued innovation and research to raise the standard of care.

The company further reported that during the 12-week, double-blind, placebo-controlled period, the safety profile of risankizumab SC remained consistent with the safety profile observed in Crohn’s disease, with no new safety risks observed. Upper respiratory tract infection, abdominal pain, and arthralgia were the most common adverse events observed among patients receiving risankizumab, and serious adverse events occurred in 0.5% of patients in the risankizumab SC group compared to 3.1% in the placebo group.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.